These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
201 related items for PubMed ID: 20421818
1. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. Aisner SC, Dahlberg S, Hameed MR, Ettinger DS, Schiller JH, Johnson DH, Aisner J, Loehrer PJ. J Thorac Oncol; 2010 Jun; 5(6):885-92. PubMed ID: 20421818 [Abstract] [Full Text] [Related]
3. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Palmieri G, Montella L, Martignetti A, Muto P, Di Vizio D, De Chiara A, Lastoria S. Cancer; 2002 Mar 01; 94(5):1414-20. PubMed ID: 11920496 [Abstract] [Full Text] [Related]
4. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs). Tiseo M, Damato A, Longo L, Barbieri F, Bertolini F, Stefani A, Migaldi M, Gnetti L, Camisa R, Bordi P, Buti S, Rossi G. Lung Cancer; 2017 Feb 01; 104():24-30. PubMed ID: 28212996 [Abstract] [Full Text] [Related]
5. Imatinib mesylate in thymic epithelial malignancies. Palmieri G, Marino M, Buonerba C, Federico P, Conti S, Milella M, Petillo L, Evoli A, Lalle M, Ceribelli A, Merola G, Matano E, Sioletic S, De Placido S, Di Lorenzo G, Damiano V. Cancer Chemother Pharmacol; 2012 Feb 01; 69(2):309-15. PubMed ID: 21710245 [Abstract] [Full Text] [Related]
6. Immunohistochemical analysis of thymic carcinoma focusing on the possibility of molecular targeted and hormonal therapies. Omatsu M, Kunimura T, Mikogami T, Hamatani S, Shiokawa A, Masunaga A, Kitami A, Suzuki T, Kadokura M, Morohoshi T. Gen Thorac Cardiovasc Surg; 2012 Dec 01; 60(12):803-10. PubMed ID: 23054618 [Abstract] [Full Text] [Related]
7. Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems. Ma Y, Li Q, Cui W, Miao N, Liu X, Zhang W, Zhang C, Wang J. Diagn Pathol; 2012 Sep 14; 7():120. PubMed ID: 22974165 [Abstract] [Full Text] [Related]
9. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. Bluthgen MV, Boutros C, Fayard F, Remon J, Planchard D, Besse B. Lung Cancer; 2016 Sep 14; 99():111-6. PubMed ID: 27565923 [Abstract] [Full Text] [Related]
10. Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. Kirzinger L, Boy S, Marienhagen J, Schuierer G, Neu R, Ried M, Hofmann HS, Wiebe K, Ströbel P, May C, Kleylein-Sohn J, Baierlein C, Bogdahn U, Marx A, Schalke B. PLoS One; 2016 Sep 14; 11(12):e0168215. PubMed ID: 27992479 [Abstract] [Full Text] [Related]
11. ¹⁸F-fluorodeoxyglucose positron emission tomography for evaluation of thymic epithelial tumors: utility for World Health Organization classification and predicting recurrence-free survival. Seki N, Sakamoto S, Karube Y, Oyaizu T, Ishihama H, Chida M. Ann Nucl Med; 2014 Apr 14; 28(3):257-62. PubMed ID: 24430867 [Abstract] [Full Text] [Related]
12. Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. Kim DJ, Yang WI, Kim SH, Park IK, Chung KY. Eur J Cardiothorac Surg; 2005 Oct 14; 28(4):611-6. PubMed ID: 16125946 [Abstract] [Full Text] [Related]
13. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Kollmannsberger C, Mayer F, Pressler H, Koch S, Kanz L, Oosterhuis JW, Looijenga LH, Bokemeyer C. Cancer; 2002 Jul 15; 95(2):301-8. PubMed ID: 12124830 [Abstract] [Full Text] [Related]
14. Thymic malignancies: from clinical management to targeted therapies. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. J Clin Oncol; 2011 Dec 20; 29(36):4820-7. PubMed ID: 22105817 [Abstract] [Full Text] [Related]
16. Clinical evaluation of a new tumour-node-metastasis staging system for thymic malignancies proposed by the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, Hirakawa A, Tateyama H, Yokoi K. Eur J Cardiothorac Surg; 2016 Feb 20; 49(2):574-9. PubMed ID: 26547095 [Abstract] [Full Text] [Related]
17. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study. Lattanzio R, La Sorda R, Facciolo F, Sioletic S, Lauriola L, Martucci R, Gallo E, Palmieri G, Evoli A, Alessandrini G, Ruco L, Rendina EA, Truini M, Chiarle R, Barreca A, Pich A, Ascani S, Remotti D, Tunesi G, Granone P, Ratto GB, Puma F, Pescarmona E, Piantelli M, Marino M, Thymic Epithelial Tumor Working Group, Carlini S, Cerasoli V, Corzani F, Melis E, Filippetti M, Canalini P, Palestro G, Lalle M, Ruffini E, Ceribelli A, Rinaldi M. Lung Cancer; 2014 Aug 20; 85(2):191-6. PubMed ID: 24908332 [Abstract] [Full Text] [Related]
18. Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors: Long-term results from a multicentre analysis of 108 cases. Cardillo G, Lucchi M, Marulli G, Infante M, Leuzzi G, Mussi A, Carleo F, Facciolo F, Voulaz E, Rea F, Rapicetta C, Lococo F. Lung Cancer; 2016 Mar 20; 93():88-94. PubMed ID: 26898620 [Abstract] [Full Text] [Related]